Other
Academic GI Cancer Consortium (AGICC)
Total Trials
3
Recruiting
0
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
Failure Rate
33.3%
1 terminated/withdrawn out of 3 trials
Success Rate
50.0%
-36.5% vs industry average
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed trials have results
Key Signals
1 with results
Enrollment Performance
Analytics
Phase 2
2(66.7%)
Phase 3
1(33.3%)
3Total
Phase 2(2)
Phase 3(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (3)
Showing 3 of 3 trials
NCT05167409Phase 2Active Not Recruiting
A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer
Role: collaborator
NCT02109445Phase 2Terminated
Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies
Role: collaborator
NCT01360853Phase 3Completed
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Role: collaborator
All 3 trials loaded